MedTrace Logo

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

NCT00101998 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 233

Last updated 2017-08-30

No results posted yet for this study

Summary

A multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in subjects with cancer pain. The study will require five visits over a five-week period.

Conditions

Interventions

DRUG

alvimopan

DRUG

placebo

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials, MD · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-01
Primary Completion
2006-05-01
Completion
2006-05-01

Countries

  • United States
  • Argentina
  • Australia
  • Canada
  • Czechia
  • Finland
  • France
  • Germany
  • Hong Kong
  • Hungary
  • India
  • Italy
  • Netherlands
  • New Zealand
  • Pakistan
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Russia
  • South Africa
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00101998 on ClinicalTrials.gov